Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Advancing The Cardiovascular Care in Cancer Patients on Chemotherapy

ACTA MEDICA INDONESIANA · Vol. 55 No. 4 (2024)

ISSN
2338-2732, 0125-9326
Terbit
2024-01-12
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Cardiotoxicity associated with chemotherapy, also known as Cancer Therapy-Related Cardiac Dysfunction (CTRCD), affects 10% of patients undergoing chemotherapy and is the most undesirable side effect of chemotherapy. Over time, it is anticipated that there would be an increase in the number of cancer patients receiving treatments that could harm their cardiovascular systems. Physicians should choose whether to continue, halt, delay, or reduce the dose of chemotherapeutic drugs to reduce the impact of cardiotoxicity. Cardiotoxicity screening and diagnosis need a variety of methods, primarily echocardiography to evaluate Left Ventricular Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS). Depending on the clinical state, these procedures may be carried out prior to, during, or following chemotherapy. It’s critical to reduce cardiovascular risk factors and offer advice on leading a healthy lifestyle before giving cancer patients medicines. There are a lot of cancer treatment facilities all around the world that don’t have evidence-based perspective cardiotoxicity scores to stratify the risk of cardiovascular problems caused by cancer therapy. Additionally, comorbid conditions like diabetes and hypertension are frequently present in cancer patients, which can have a significant impact on clinical outcomes and cancer treatment. Therefore, this article aims to discuss assessment methods, clinical practice guidance, and prevention of CTRCD.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 153 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Halu Oleo
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Eka GinanjarAfiliasi tidak diketahui7
Siti SetiatiAfiliasi tidak diketahui6
Idrus AlwiAfiliasi tidak diketahui6
Annisa Puspitasari NachrowiAfiliasi tidak diketahui5
Andhika RachmanAfiliasi tidak diketahui3
Sally Aman NasutionAfiliasi tidak diketahui3
Dono AntonoAfiliasi tidak diketahui3
Arif MansjoerAfiliasi tidak diketahui3
Mirza AntoniAfiliasi tidak diketahui2
Lia Perwita SariAfiliasi tidak diketahui2
RiswaniAfiliasi tidak diketahui2
Nur PaikahAfiliasi tidak diketahui2
Kuntjoro HarimurtiAfiliasi tidak diketahui2
Lugyanti SukrismanAfiliasi tidak diketahui2
Evy YunihastutiAfiliasi tidak diketahui2
Nurul Inayah RahmaniAfiliasi tidak diketahui2
Ika Prasetya WijayaAfiliasi tidak diketahui2
Hamzah ShatriAfiliasi tidak diketahui2
Radiyati Umi PartanAfiliasi tidak diketahui2
Natalis RansiUniversitas Halu Oleo1
Waode Hardianas ShalawatiAfiliasi tidak diketahui1
Andi Tenri AmpaUniversitas Halu Oleo1
NurlianaAfiliasi tidak diketahui1
Maghfirah Sari AzisAfiliasi tidak diketahui1
Imran - ImranAfiliasi tidak diketahui1
Nurkhalis NurkhalisAfiliasi tidak diketahui1
Kurnia Fitri JamilAfiliasi tidak diketahui1
Faissal MalikAfiliasi tidak diketahui1
Abdullah Akhyar NasutionAfiliasi tidak diketahui1
Ibrahim ChalidAfiliasi tidak diketahui1
Nur HafniAfiliasi tidak diketahui1
Syahrir AziziAfiliasi tidak diketahui1
Christopher SuwitaAfiliasi tidak diketahui1
Astrid KarinaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Advancing The Cardiovascular Care in Cancer Patients on Chemotherapy</dc:title>
	<dc:creator>Yamin, Muhammad</dc:creator>
	<dc:creator>Salim, Simon</dc:creator>
	<dc:creator>Azizi, Muhammad Syahrir</dc:creator>
	<dc:creator>Rusdi, Lusiani</dc:creator>
	<dc:creator>Sudoyo, Aru Wisaksono</dc:creator>
	<dc:creator>Putri, Anneira Amanda</dc:creator>
	<dc:subject xml:lang="en-US">cardiac disease</dc:subject>
	<dc:subject xml:lang="en-US">cardiotoxicity</dc:subject>
	<dc:subject xml:lang="en-US">CTRCD</dc:subject>
	<dc:subject xml:lang="en-US">chemotherapy</dc:subject>
	<dc:subject xml:lang="en-US">cancer</dc:subject>
	<dc:description xml:lang="en-US">Cardiotoxicity associated with chemotherapy, also known as Cancer Therapy-Related Cardiac Dysfunction (CTRCD), affects 10% of patients undergoing chemotherapy and is the most undesirable side effect of chemotherapy. Over time, it is anticipated that there would be an increase in the number of cancer patients receiving treatments that could harm their cardiovascular systems. Physicians should choose whether to continue, halt, delay, or reduce the dose of chemotherapeutic drugs to reduce the impact of cardiotoxicity. Cardiotoxicity screening and diagnosis need a variety of methods, primarily echocardiography to evaluate Left Ventricular Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS). Depending on the clinical state, these procedures may be carried out prior to, during, or following chemotherapy. It’s critical to reduce cardiovascular risk factors and offer advice on leading a healthy lifestyle before giving cancer patients medicines. There are a lot of cancer treatment facilities all around the world that don’t have evidence-based perspective cardiotoxicity scores to stratify the risk of cardiovascular problems caused by cancer therapy. Additionally, comorbid conditions like diabetes and hypertension are frequently present in cancer patients, which can have a significant impact on clinical outcomes and cancer treatment. Therefore, this article aims to discuss assessment methods, clinical practice guidance, and prevention of CTRCD.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2024-01-12</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2440</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 55 No. 4 (2023): Acta Medica Indonesiana; 494</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2440/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2024 Muhammad Yamin</dc:rights>
</oai_dc:dc>